# A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects

> **NCT02601625** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 30 (actual)

## Conditions studied

- Safety
- Pharmacokinetics
- Healthy Subjects

## Interventions

- **DRUG:** Anifrolumab SC injection (300mg)
- **DRUG:** Anifrolumab IV infusion (300mg)
- **DRUG:** Anifrolumab SC infusion (600mg)
- **DRUG:** Anifrolumab placebo SC injection (300mg)
- **DRUG:** Anifrolumab placebo IV infusion (300mg)
- **DRUG:** Anifrolumab placebo SC infusion (600mg)

## Key facts

- **NCT ID:** NCT02601625
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-16
- **Primary completion:** 2016-05-25
- **Final completion:** 2016-05-25
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02601625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02601625, "A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02601625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*